|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Press Release - Octapharma comments on the CADTH Report on cost-effectiveness of Octaplas®
May 8, 2009
Press release - Swine Influenza Virus (SIV) Outbreak and Implications in the Transfusion of the Biopharmaceutical Pooled and Virally Inactivated Plasma for Transfusion Octaplas®
April 29, 2009
Press release - The Board of the Octapharma Group appoints Mr. Flemming Nielsen and Mr. Dennis Curtin as Members of the Board
April 22, 2009
Press release - The French Health and Sports Minister grants the founder of the Octapharma Group, Mr. Wolfgang Marguerre, the French Legion of Honor during a visit to Octapharma' s facilities in Lingolsheim, France
April 21, 2009
Welcome to Octapharma!
Octapharma, a Swiss-based company, is an independent, global plasma fractionation specialist. Its core business is the development, production and sale of high quality plasma derivatives.
The information provided on the Octapharma website is based on world-wide business and approved international product specifications. As registration status and prescribing information for our products vary from country to country, you are encouraged to contact your local Octapharma office for country specific information. In addition, Octapharma is developing specific country web pages which may also be referenced. US residents, for example, should refer to Octapharma USA on the pull down list below for FDA approved product information:
Last update 5/8/2009, © Octapharma AG |
|
 |
|
|
|
